STOPPIT-2 was a multi-centre randomised controlled trial, funded by the NIHR HTA Programme investigating whether the Arabin cervical pessary prevents preterm birth in women with a twin pregnancy and a short cervix. Patients with a short cervix (≤30mm) who agree to participate in the treatment phase of the study were randomised to either treatment with the Arabin cervical pessary or to standard care (no additional treatment).
STOPPIT-2 randomised 500 participants.
The primary endpoint of the trial is birth before 34+0 weeks following the spontaneous onset of labour.
STOPPIT-2 was led by Professor Jane Norman based at the University of Edinburgh.
For more information see the STOPPIT-2 Study Website
- CHaRT email; email@example.com